PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1450367602	rs370803989	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for D188N = *33 is 46.56% compared to *1 (no variants).	fluoxetine
1184472218	rs2032582	PMID:24663076	ABCB1	Allele A is associated with increased response to fluoxetine in children with Depressive Disorder as compared to allele C.	yes	< 0.05	83		European	Efficacy	true	After 8 weeks of treatment T allele carriers showed higher improvements on the CDI (P=0.03), OCI-CV (P=0.001) and CGI-I (P<0.001) scales. After 12 weeks of treatment patients carrying the T allele showed significantly higher improvements in the OCI-CV (P=0.01) and SCARED (P=0.006) scales.	fluoxetine
1450664564	rs17878459	PMID:21692664	CYP2C19	Allele C is associated with decreased sensitivity to fluoxetine as compared to allele G.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. The construct includes E92D and I331V."	fluoxetine
1184518303	CYP2C19*1; CYP2C19*9	PMID:21692664	CYP2C19	CYP2C19 *9 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and troglitazone as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; sertraline; troglitazone
1184511379	rs6313	PMID:16302021	HTR2A	Allele G is not associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to allele A.	no	= 0.446	224		East Asian	Efficacy	false	Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment.	fluoxetine
1184169374	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*41	PMID:23545896	CYP2D6	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	no	= 0.619	184		Multiple groups, predominantly European ancestry (90.2%)	Toxicity	false	The association is for impact of CYP2D6 (P=0.619) or CYP2C19 (P=0.391) on the occurrence of significant side effects in all trials overall (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders. A similar approach was taken for side effects.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1448602202	rs9361235	PMID:28025020	HTR1B	Genotypes CC + TT is associated with increased response to fluoxetine in children with Depressive Disorder, Major as compared to genotype CT.	yes	= 0.00059	84		European	Efficacy	true		fluoxetine
1450367586	rs550527959	PMID:28494448	CYP2C19	Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.	yes	< 0.05			Unknown	Metabolism/PK	false	Caution: The variant might be together with rs4244285. Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. The article names the construct *2g(D360V), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for D360V is 30.24% compared to *1 (no variants).	fluoxetine
1184472200	rs1045642	PMID:24663076	ABCB1	Allele G is not associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to allele A.	no	= 0.001	83		European	Metabolism/PK	true		fluoxetine
1183624094	CYP2D6*1; CYP2D6*1xN	PMID:14726986	CYP2D6	CYP2D6 *1/*1xN is associated with decreased dose-corrected plasma concentrations of fluoxetine when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	yes	= 0.01	64		European	Metabolism/PK	false	Diplotypes found in study: *1/*1 (41); *1/*4 (17); *1/*6 (2); *4/*4 (1); *1/*1XN (3). The C/D plasma concentrations of fluoxetine were overall significantly (P<0.01, r=¿0.36) related to the number of active CYP2D6 genes. The mean±SD C/D plasma concentrations of fluoxetine (nmol/l/mg) were 3.0±7.6 with two active genes (n=41) and 7.3±4.5 with more than two active genes (n=3).	fluoxetine
1183623583	CYP2D6*1; CYP2D6*1xN; CYP2D6*4	PMID:16236141	CYP2D6	CYP2D6 *1/*1xN is associated with increased S-norfluoxetine/S-fluoxetine ratios when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 *4/*4.	not stated		7		European	Metabolism/PK	false	Dose-normalized plasma levels of individual enantiomers and of the active moiety did not differ significantly across groups. However, the highest S-norfluoxetine/S-fluoxetine ratios were found in subjects with the ultrarapid metabolizer genotype (n=6) (median 1.75) and the lowest in the only subject with the poor metabolizer genotype (0.1).no p-value given.	fluoxetine
1184518542	CYP2C19*1; CYP2C19*16	PMID:21692664	CYP2C19	CYP2C19 *16 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and ticlopidine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; sertraline; ticlopidine
1184511375	rs57098334	PMID:16302021	SLC6A4	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with increased response to fluoxetine in people with Depressive Disorder, Major.	no	= 0.246	224		East Asian	Efficacy	false	Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment.	fluoxetine
1450664546	rs181297724	PMID:21692664	CYP2C19	Allele C is associated with decreased sensitivity to fluoxetine, ketoconazole, sertraline or ticlopidine as compared to allele G.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. Construct included A161P and I331V but not *2 key SNP."	fluoxetine; ketoconazole; sertraline; ticlopidine
1450367591	rs763625282	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay, the article names the variant *3C (M136K). However it is not clear if the *3 signature SNP is included but the *3 signature SNP by itself results in not detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for M136K is 63.65% compared to *1 (no variants).	fluoxetine
1183617434	CYP2D6*1; CYP2D6*4	PMCID:PMC2291379	CYP2D6	CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.	yes	= 0.03	833		European	Dosage,Efficacy	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.) SSRIs were grouped together for this analysis (32.5 % of patients were taking paroxetine; 13.4% fluvoxamine;11.6% fluoxetine; 7.3% sertraline;4.6% citalopram;0.1% escitalopram.  Mean SSRI dose was significantly lower at the 3rd  prescription (difference 0.17 DDD) but not significant for the following prescriptions.   Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1184472195	rs2032582	PMID:24663076	ABCB1	Allele C is not associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to allele A.	no	= 0.001	83		European	Metabolism/PK	true		fluoxetine
1184518528	CYP2C19*1; CYP2C19*15	PMID:21692664	CYP2C19	CYP2C19 *15 is associated with decreased sensitivity to fluoxetine and tranylcypromine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluoxetine; tranylcypromine
1184511361	rs6295	PMID:16302021	HTR1A	Genotype CC is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.009	224		East Asian	Efficacy	false	Alleles reported as found in paper. Gene is on the negative strand association but it is unclear if this was taken into account when the genotype was describe in the article. Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment.	fluoxetine
1184483970	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:20640435	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.04	85		European	Efficacy	false	Treatment outcome was assessed with the MADRS scale.	citalopram; fluoxetine; paroxetine
1448602188	rs9361233	PMID:28025020	HTR1B	Genotypes CC + TT is associated with increased response to fluoxetine in children with Depressive Disorder, Major as compared to genotype CT.	yes	= 0.0018	84		European	Efficacy	true		fluoxetine
1184509830	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:14573314	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of Psychomotor Agitation when treated with fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.01	36		European	Toxicity	false		fluoxetine
1450367596	rs145328984	PMID:28494448	CYP2C19	Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R73C = *30 is 21.28% compared to *1 (no variants).	fluoxetine
1450367570	rs778258371	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Caution: The variant might be together with rs4244285. Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. The article names the construct *2E(M271I), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for M271I is 32.38% compared to *1 (no variants).	fluoxetine
1184509880	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:22885912	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.004	88		East Asian	Efficacy	false	For statistical power, the samples were enriched with the l/l carriers 5-HTTLPR polymorphism, L/L carriers are rare in Koreans.	fluoxetine; sertraline
1184169142	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*41	PMID:23545896	CYP2D6	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	no	= 0.743	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	The association is for impact of CYP2D6 (P=0.743) or CYP2C19 (P=0.939) on overall response (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1183921586	CYP2D6*1; CYP2D6*1xN; CYP2D6*2	PMID:22775532	CYP2D6	CYP2D6 *1/*1xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	no	> 0.05	39		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).32 patients were CYP2D6 EMs, 2 were UMs, 4 were IMs, and 1 patient was a PM. Exploratory association analysis of response to all 108 drug trials found a significant effect of CYP2D6 metabolizer status on response (Fisher's exact test: p=0.021) when comparing the patients with reduced CYP2D6 activity (IMs and PMs) to EMs or UMs, but no information regarding the direction of the association is given. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	citalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1451503520	CYP3A5*1; CYP3A5*3	PMCID:PMC8441053	CYP3A5	CYP3A5 *1/*1 + *1/*3 is associated with decreased severity of Anxiety Disorders when treated with fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP3A5 *3/*3 (assigned as intermediate metabolizer phenotype) .	yes	= 0.037	60		Latino	Efficacy	false	"Patients who
were CYP3A5 expressors (n = 22), had a lower distribution of
Beck´s anxiety scores than CYP3A5 non expressors (3.5 (1–11.5)
vs. 9 (5–15)"	fluoxetine
1183624105	CYP2D6*1; CYP2D6*1xN	PMID:14726986	CYP2D6	CYP2D6 *1/*1xN is not associated with increased differences in C/D plasma concentrations of norfluoxetine or active moiety when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	no	= 0.01	64		European	Metabolism/PK	false	Diplotypes found in study: *1/*1 (41); *1/*4 (17); *1/*6 (2); *4/*4 (1); *1/*1XN (3).	fluoxetine
1184484028	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:12476327	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.007	121		East Asian	Efficacy	false	Response was assessed using HAM-D scale.	fluoxetine
1451499681	rs3892097	PMID:34529603	CYP2D6	Genotype CT is associated with increased concentrations of fluoxetine in men with Alcoholism and Depressive Disorder, Major as compared to genotype CC.	yes	< 0.001	101		Unknown	Efficacy	false	Heterozygotes also had higher scores on side effects. Alleles complemented to plus chromosomal strand. No homozygotes for minor allele were found.	fluoxetine
1184518588	CYP2C19*1; CYP2C19*19	PMID:21692664	CYP2C19	CYP2C19 *19 is associated with decreased sensitivity to fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine and tranylcypromine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluoxetine; fluvoxamine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine
655387194	rs61888800	PMCID:PMC4272010	BDNF	Genotype GG is associated with increased response to antidepressants, desipramine and fluoxetine in people with Depressive Disorder, Major.	not stated	= 0.02	272	264	Latino	Efficacy	false	"Outcome with the two drugs was combined for analysis.  Not found to be associated with remission vs non-remission.  Found to be associated with reduction in HAM-D21 score after adjusting for age, sex, medication, and
baseline HAM-D21 score."	antidepressants; desipramine; fluoxetine
1446903828	CYP2D6 poor metabolizers	PMID:22733128	CYP2D6	CYP2D6 poor metabolizers are not associated with discontinuation of amitriptyline or fluoxetine in people with Depressive Disorder, Major.	no		100		Unknown	Toxicity	false	Patients received either 20 mg/day fluoxetine or 75 mg/day amitriptyline. 4 UMs (more than two functional CYP2D6 alleles) discontinued treatment within the first 4 weeks, whereas no PM (no functional CYP2D6 allele) did so within 12 weeks. There were differences across CYP2D6 groups in the rate of ADP discontinuation at week 4 (P<0.01). The CYP2D6 activity value assigned to the reference allele *1 and *2 was 1, to *3, *4, *4xN, *5 and *6 was 0, to *10 or *17 was 0.5 and to multiplications of active alleles (*1xN or *2xN) was 2. Alleles or diplotypes found in study population or if patients received any co-medication were not reported.	amitriptyline; fluoxetine
981501099	rs6265	PMID:20016225	BDNF	Allele T is associated with decreased likelihood of side effects when treated with fluoxetine in people with Depressive Disorder, Major as compared to allele C.	no				East Asian	Toxicity	false	Information is minimal because full-text was not accessible.	fluoxetine
1184512692	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:19468717	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.032	362		East Asian	Efficacy	false	"For 5-HTTLPR genotyping, the homozygotes were designated as L/L (528 bp, 16
copies) or S/S (484 bp, 14 copies), and the heterozygotes designated as L/S."	citalopram; fluoxetine; paroxetine
1450367581	rs770829708	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Caution: The variant might be together with rs4244285. Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. The article names the construct *2F(D341N), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for D341N is 14.01% compared to *1 (no variants).	fluoxetine
1451503541	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMCID:PMC8441053	CYP2C19	CYP2C19 *1/*17 + *17/*17 is associated with decreased severity of Depression when treated with fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizer phenotype) .	yes	< 0.01	18		Latino	Efficacy	false	CYP2C19 ultrarapid metabolism had depression scores lower than CYP2C19 intermediate metabolizers (1.5 (0.25–3.5) vs. 5 (4–17.25). There were 5 UM and 13 IM, majority of patients were EM (n=40) and 2 PM (*2/*2). CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560) were measured.	fluoxetine
1184472237	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:24663076	CYP2D6	CYP2D6 *1/*1 is not associated with response to fluoxetine in children with Depressive Disorder as compared to CYP2D6 *5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6.	no		83		European	Efficacy	true	No difference in response was observed between the CYP2D6 genotype groups (*1/*1xN, *1/*1, *5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6).	fluoxetine
1183634361	rs56294817	PMID:19481584	HES6	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele C.	no	> 0.05	278		Unknown	Efficacy	false		citalopram; fluoxetine; paroxetine
1183633851	rs2433320	PMCID:PMC3762623		Genotype GG is associated with decreased HAMD scores when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotypes AA + AG.	yes	= 0.0145	185		East Asian	Efficacy	false		fluoxetine
1450372683	rs7905446	PMID:30874608	HTR7	Genotype TT is associated with decreased response to fluoxetine or paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT.	yes	= 0.008	266		European	Efficacy	false	"A 'good' response was determined as a 50% reduction in symptoms or episode frequency during the course of the illness.

This analysis was carried out on patients who were treated with fluoxetine or paroxetine. This association remained statistically significant in the paroxetine group, but significance was lost in the fluoxetine group."	fluoxetine; paroxetine
1183634353	rs1374385	PMID:19481584	HES6	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no	> 0.05	278		Unknown	Efficacy	false		citalopram; fluoxetine; paroxetine
1183624113	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:14726986	CYP2C9	CYP2C9 *1/*2 + *1/*3 is associated with increased dose-corrected plasma concentrations of fluoxetine and the active moiety in patients with two functional CYP2D6 alleles when treated with fluoxetine in people with Mental Disorders as compared to CYP2C9 *1/*1.	yes	= 0.05	38		European	Metabolism/PK	false	Association was found in dependency on CYP2D6; only inpatients with two functional CYP2D6 alleles.	fluoxetine
1184518567	CYP2C19*1; CYP2C19*18	PMID:21692664	CYP2C19	CYP2C19 *18 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole and ticlopidine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; ticlopidine
1184513240	rs57098334	PMID:17018806	SLC6A4	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.	yes	= 0.01	136		East Asian	Efficacy	false	Patients carrying the 12/12 VNTRs were compared to 9 and 10 VNTRs.	fluoxetine; sertraline
1451254722	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:19468717	SLC6A4	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	no	= 0.617	362		East Asian	Efficacy	false		citalopram; fluoxetine; paroxetine
655386196	rs25531	PMID:15993855	SLC6A4	Genotypes CC + CT are associated with increased risk of reduced response when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotype TT.	no		96		Unknown	Efficacy	false	"Stated as ""suggestive evidence""."	fluoxetine
1184169426	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:23545896	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	no	= 0.939	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	The association is for impact of CYP2D6 (P=0.743) or CYP2C19 (P=0.939) on overall response (defined see below). A nonsignificant trend for association of predicted CYP2C19 metabolizer status with treatment response to sertraline (P=0.064) was found but the direction of the association was not reported. Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1448631838	CYP2C19 normal metabolizer genotype	PMID:28470107	CYP2C19	CYP2C19 normal metabolizer genotype is not associated with likelihood of aggression when treated with citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and Selective serotonin reuptake inhibitors in people with Anxiety Disorders and Depression.	no		18	99	Unknown	Toxicity	false	"genotypes were not significantly different between cases (aggression while on SSRIs) and heathy blood donor controls. But authors state ""However, these numbers are too small to draw any conclusion."""	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; Selective serotonin reuptake inhibitors
1448631828	CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes	PMID:28470107	CYP2D6	CYP2D6 normal metabolizer and ultra-metabolizer genotypes is not associated with likelihood of aggression when treated with citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and Selective serotonin reuptake inhibitors in people with Anxiety Disorders and Depression.	no		18	99	Unknown	Toxicity	false	"genotypes were not significantly different between cases (aggression while on SSRIs) and heathy blood donor controls. Cases had no PMs. But authors state ""However, these numbers are too small to draw any conclusion."""	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; Selective serotonin reuptake inhibitors
1184513231	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:17018806	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.003	136		East Asian	Efficacy	false		fluoxetine; sertraline
1183624148	CYP2D6*1; CYP2D6*4	PMID:11386497	CYP2D6	CYP2D6 *4/*4 is associated with significantly higher (S)-fluoxetine and lower and (S)-norfluoxetine concentrations when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	yes	= 0.05	11		Unknown	Metabolism/PK	false	Patients were were comedicated with risperidone. Three patients were genotyped as PMs (CYP2D6*4/CYP2D6*4), two as heterozygous (CYP2D6*1/CYP2D6*4) EMs (HT EMs), and six as homozygous (CYP2D6*1/CYP2D6*1) EMs (HM EMs). A gene-dose effect was found. The S-fluoxetine concentrations were higher in het EMs compared to homo EMs but not at a significant level also the S-norfluoxetine concentrations were lower in het EMs compared to homo EMs.	fluoxetine
1184472258	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:24663076	CYP2C9	CYP2C9 *1/*1 is not associated with response to fluoxetine in children with Depressive Disorder as compared to CYP2C9 *2/*3 + *3/*3.	no		83		European	Efficacy	true	No difference in response was observed between the CYP2C9 genotype groups. Five patients were classified as PM, with two defective alleles (*2/*3: n=3; *3*3: n=2). Twenty patients carried one defective allele and were classified as IM (*1/*2 or *1/*3). No defective alleles were detected in 58 patients identified as EM (*1/*1).	fluoxetine
1183623634	CYP2D6*1; CYP2D6*1xN	PMID:16236141	CYP2D6	CYP2D6 *1/*1xN is not associated with differences in Dose-normalized plasma levels of individual enantiomers and of the active moiety when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	no		78		European	Metabolism/PK	false		fluoxetine
1450367762	CYP2C19*1; CYP2C19*32	PMID:28494448	CYP2C19	CYP2C19 *32 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for H99R is 34.93% compared to *1 (no variants).	fluoxetine
981502189	rs4680	PMID:20584552	COMT	Genotype GG is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to genotypes AA + AG.	no	= 0.071	64		Multiple groups, probably White (Spanish mental health center).	Dosage,Efficacy	false	"However, authors note that GG subjects were responders ""slightly more"" than AG or AA.
It was also noted that there was no placebo group in this trial.  The association tested was with response at 4 weeks."	fluoxetine
1183624163	CYP2D6*1; CYP2D6*4; CYP2D6*5; CYP2D6*10	PMID:14716707	CYP2D6	CYP2D6 *1/*1 + *1/*10 are not associated with increased risk of side effects when treated with fluoxetine or nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *4/*4 + *4/*5.	no		125		Unknown	Toxicity	false	"Inferred as EMs (wild type (CYP2D6*1) or intermediate (CYP2D6*2, *9 or *10)) (n=115) specific diplotypes for EM group are not reported; PMs (n=10) are *4/*4 or *4/*5. No p-value given. 3 PMs who did not complete an adequate trial one on fluoxetine and one on nortriptyline discontinued between weeks 1 and 3,
and one patient on fluoxetine discontinued between weeks 3 and 6."	fluoxetine; nortriptyline
1184518120	CYP2C19*1; CYP2C19*8	PMID:21692664	CYP2C19	CYP2C19 *8 is associated with decreased sensitivity to fluconazole, fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluconazole; fluoxetine; fluvoxamine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine; troglitazone
1450367750	CYP2C19*1; CYP2C19*31	PMID:28494448	CYP2C19	CYP2C19 *31 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for K28I is 43.04% compared to *1 (no variants).	fluoxetine
1183684600	CYP2D6*1; CYP2D6*17	PMID:12438554	CYP2D6	CYP2D6 *17 is associated with decreased clearance of fluoxetine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	not stated		2	2	Unknown	Metabolism/PK	false	Intrinsic clearance decreased 0.034 ml/pmol P450/min with *17 as compared to 0.23 ml/pmol P450/min with *1. *1 cDNA (Kimura sequence), *17 T107L, R296C and S486T	fluoxetine
1184165857	CYP2D6 normal metabolizers	PMID:12173784	CYP2D6	CYP2D6 normal metabolizers is associated with increased dextromethorphan (DM):dextrorphan (DX) metabolic ratio after 8 days fluoxetine when treated with fluoxetine in healthy individuals.	not stated		8		Unknown	Metabolism/PK	false	Patients were phenotyped with dextromethorphan. The association is in comparison to metabolic ratio at baseline. All subjects (n=8) showed 338-6386% increase. Ratio of urinary dextromethorphan (DM):dextrorphan (DX) was measured at baseline and after 8 days treatment.  Eight subjects per drug received once-daily dosing of an SSRI for 8 days: fluoxetine 60 mg/day, fluvoxamine 100 mg/day, paroxetine 20 mg/day, or sertraline 100 mg/day.	fluoxetine
1183620603	CYP2D6*1; CYP2D6*4	PMID:14639062	CYP2D6	CYP2D6 *4/*4 is associated with increased fluoxetine plasma concentration when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	yes	= 0.004	12		European	Metabolism/PK	false	Note: only the genotype for PM was given; the EM are only referred as extensive metabolizer in the paper without any specification of alleles. Fluoxetine plasma concentration in both subjects was significantly higher than in 10 EM (178.5 ± 68.6 µg/L versus 49.4 ± 40.7 µg/L, P = 0.004). Blood samples were obtained at the beginning of the treatment for genetic determination and after steady-state concentration was reached (at least 5 weeks) for plasma drug quantification. Fluoxetine (20 mg/d) was administered to 12 patients,	fluoxetine
981750780	rs6295	PMID:19590397	HTR1A	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1450931459	rs17162912	PMID:29953682	DISP1	Allele C is not associated with response to citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to allele T.	no	> 0.05	112		European	Efficacy	false	No significant association between this variant and SRI or SSRI response using additive or dominant models. Note that this allele was not in HWE in the cohort (p=0.0008).	citalopram; clomipramine; fluoxetine; fluvoxamine; paroxetine; sertraline
981502205	rs25531	PMID:20584552	SLC6A4	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.	no		64		Multiple groups, probably White (Spanish mental health center).	Dosage,Efficacy	false	There was no placebo group in this trial.  The association tested was with response at 4 weeks.	fluoxetine
1183684592	CYP2D6*1; CYP2D6*10	PMID:12438554	CYP2D6	CYP2D6 *10 is associated with decreased clearance of fluoxetine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	not stated		2	2	Unknown	Metabolism/PK	false	Intrinsic clearance decreased 0.004 ml/pmol P450/min with *10 as compared to 0.23 ml/pmol P450/min with *1. *1 cDNA (Kimura sequence) *10 has P34S (100C>T), S486T	fluoxetine
1450367730	rs1463550071	PMID:28494448	CYP2C19	Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for N403I is 33.25% compared to *1 (no variants).	fluoxetine
1183623695	CYP2C9*1; CYP2C9*2	PMID:16236141	CYP2C9	CYP2C9 *1/*1 is not associated with differences in dose-normalized plasma levels of individual enantiomers and of the active moiety when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2C9 *1/*2 + *2/*2.	no	= 0.05	78		European	Metabolism/PK	false		fluoxetine
1184518425	CYP2C19*1; CYP2C19*10	PMID:21692664	CYP2C19	CYP2C19 *10 is associated with decreased sensitivity to fluoxetine as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluoxetine
981750786	rs6313	PMID:19590397	HTR2A	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1448265433	rs4570625	PMID:27660918	TPH2	Genotype TT is associated with increased response to fluoxetine in children with Mental Disorders as compared to genotypes GG + GT.	yes	= 0.00002	79		European	Efficacy	true	Please note the association was only significant using the GAF/CGAS scale as outcome measure. Effect of HTR1B rs130058 on clinical improvement was measured by differences in scores obtained in GAF/CGAS, CDI, OCI-CV, SCARED, CGI-S, and CGI-I scales  after fluoxetine treatment. For the other scales the results were not significantly different between the genotypes.	fluoxetine
1183684608	CYP2D6*1; CYP2D6*2	PMID:12438554	CYP2D6	CYP2D6 *2 is associated with decreased clearance of fluoxetine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	not stated		2	2	Unknown	Metabolism/PK	false	Intrinsic clearance decreased 0.059 ml/pmol P450/min with *2 as compared to 0.23 ml/pmol P450/min with *1. *1 cDNA (Kimura sequence), *2 R296C and S486T	fluoxetine
1450367740	CYP2C19*1; CYP2C19*29	PMID:28494448	CYP2C19	CYP2C19 *29 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for K28I is 43.04% compared to *1 (no variants).	fluoxetine
981750795	rs6311	PMID:19590397	HTR2A	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1184169499	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:23545896	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	no	= 0.391	184		Multiple groups, predominantly European ancestry (90.2%)	Toxicity	false	The association is for impact of CYP2D6 (P=0.619) or CYP2C19 (P=0.391) on the occurrence of significant side effects in all trials overall (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders. A similar approach was taken for side effects.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1183633948	rs10008257	PMCID:PMC3762623		Allele G is not associated with differences in response when treated with fluoxetine in people with Depressive Disorder, Major as compared to allele A.	no	= 0.0145	185		East Asian	Efficacy	false		fluoxetine
981502225	rs495794	PMID:22795047	SRP19	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.017	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	citalopram; fluoxetine; paroxetine; sertraline
1450367712	rs764137538	PMID:28494448	CYP2C19	Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R261W is 9.56% compared to *1 (no variants).	fluoxetine
1451499280	rs3892097	PMID:34529603	CYP2D6	Genotype CC is associated with increased response to fluoxetine in men with Alcoholism and Depressive Disorder, Major as compared to genotype CT.	yes	= 0.005	101		Unknown	Efficacy	false	as measured by lower Hamilton Rating Scale for Depression scores at the end of the treatment (lower score = more effective). Heterozygotes also had higher scores on side effects. Alleles complemented to plus chromosomal strand. No homozygotes for minor allele were found.	fluoxetine
981750801	rs7997012	PMID:19590397	HTR2A	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1183623961	CYP2D6*1; CYP2D6*4; CYP2D6*6	PMID:14726986	CYP2D6	CYP2D6 *4 + *6 is associated with increased dose-corrected plasma concentrations of fluoxetine when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	yes	= 0.01	64		European	Metabolism/PK	false	Diplotypes found in study: *1/*1 (41); *1/*4 (17); *1/*6 (2); *4/*4 (1); *1/*1XN (3). The C/D plasma concentrations of fluoxetine were overall significantly (P<0.01, r=¿0.36) related to the number of active CYP2D6 genes. The mean±SD C/D plasma concentrations of fluoxetine (nmol/l/mg) were 16.7 for the only patient with zero active genes, 17.2±8.2 for patients with one active gene (n=19), 13.0±7.6 with two active genes (n=41).	fluoxetine
1183623705	CYP2C9*1; CYP2C9*3	PMID:16236141	CYP2C9	CYP2C9 *1/*1 is not associated with differences in dose-normalized plasma levels of individual enantiomers and of the active moiety when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2C9 *1/*3.	no	= 0.05	78		European	Metabolism/PK	false		fluoxetine
981502232	rs153549	PMID:22795047	REEP5	Allele A is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.0089	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The A allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the A allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the G allele."	citalopram; fluoxetine; paroxetine; sertraline
1448265419	rs130058	PMID:27660918	HTR1B	Genotypes AA + TT are associated with increased response to fluoxetine in children with Mental Disorders as compared to genotype AT.	yes	= 0.00009	78		European	Efficacy	true	Please note the association was only significant using the GAF/CGAS scale as outcome measure. Effect of HTR1B rs130058 on clinical improvement was measured by differences in scores obtained in GAF/CGAS, CDI, OCI-CV, SCARED, CGI-S, and CGI-I scales  after fluoxetine treatment. For the other scales the results were not significantly different between the genotypes.	fluoxetine
981750815	rs1800532	PMID:19590397	TPH1	Allele T is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1450367721	rs1267723490	PMID:28494448	CYP2C19	Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for I327N is 24.85% compared to *1 (no variants).	fluoxetine
981750809	rs1805054	PMID:19590397	HTR6	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
981502239	rs153560	PMID:22795047	REEP5	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.0036	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	citalopram; fluoxetine; paroxetine; sertraline
1183689490	rs28401781	PMID:24192121	ABCB1	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.267	284		East Asian	Efficacy	false	Allele T was more frequent in the responders group. This association did not remain statistically significant after correction for false-discovery rate and genotypes were not significantly associated. Please note; alleles have been complemented to the plus chromosomal strand. This SNP was in strong LD with rs4148739.	citalopram; fluoxetine; paroxetine; sertraline
981750822	rs1386494	PMID:19590397	TPH2	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1184169526	CYP2D6 normal metabolizers	PMID:23545896	CYP2D6	CYP2D6 normal metabolizers is associated with a trend of treatment response when treated with fluoxetine in people with Obsessive-Compulsive Disorder.	no	= 0.056	66		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	Compared CYP2D6 EM to non-EM (UM, IM and PM) All nine non-EM (genotype for fluoxetine treated people are not reported) being nonresponders compared with 17 EM who were responders and 40 who were nonresponders. Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	fluoxetine
769171579	rs334558	PMID:18195729	GSK3B	Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.002	168		East Asian	Efficacy	false		citalopram; fluoxetine
1184518462	CYP2C19*1; CYP2C19*13	PMID:21692664	CYP2C19	CYP2C19 *13 is not associated with sensitivity to celecoxib, fluoxetine, ketoconazole, omeprazole, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; omeprazole; ticlopidine; tranylcypromine; troglitazone
1183944245	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:10683861	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased improvement based on change of HAM-D score after antidepressant medication when treated with fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.0153	120		East Asian	Efficacy	false	PCR: (5'-GGCGTTGCCGCTCTGAATGC), and (5'-GAGGGACTGAGCTGGACAACCAC), corresponding to bases -1416-1397 and -910-889 respectively. 5-HTTLPR gave five alleles differing by 44 bp (14, 16, 18, 20, 22 copies of a repetitive sequence comprising a GC-rich 20-23 bp. The most prevalent allele of the 5-HTTLPR polymorphism for the promoter region in the Korean population was the shortest allele, the 14-copy allele. This allele is designated s and all others are designated l.	fluoxetine; paroxetine
1450367703	rs1349931378	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for S303N is 39.59% compared to *1 (no variants).	fluoxetine
1183623722	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:16236141	CYP2C9	CYP2C9 *1/*1 is associated with dose-normalized R-fluoxetine concentrations and and the active moiety in CYP2D6*1/*1 patients when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2C9 *2 + *3.	no	= 0.05	49		European	Metabolism/PK	false	Association only found in a subset of subjects which are carriers for two functional CYP2D6 alleles.	fluoxetine
1184518450	CYP2C19*1; CYP2C19*11	PMID:21692664	CYP2C19	CYP2C19 *11 is not associated with sensitivity to celecoxib, fluoxetine, ketoconazole, omeprazole, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluoxetine; ketoconazole; omeprazole; ticlopidine; tranylcypromine; troglitazone
1451255600	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:16236141	CYP2D6	CYP2D6 *1/*1 is not associated with metabolism of fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*4 + *1/*3 + *1/*5 + *1/*6.	no	= 0.05	78		European	Metabolism/PK	false	One patient was *4/*4 and excluded from analysis. Dose-normalized plasma levels of individual enantiomers and of the active moiety did not differ significantly across groups. However, the highest S-norfluoxetine/S-fluoxetine ratios were found in subjects with the ultrarapid metabolizer genotype (n=6) (median 1.75) and the lowest in the only subject with the poor metabolizer genotype (0.1). Of the remaining patients, 22 carried one detrimental allele (CYP2D6*1/*3, n=3; CYP2D6*1/*4, n=15; CYP2D6*1/*5, n=2; CYP2D6*1/*6, n=2) and 55 showed no defective alleles.	fluoxetine
1184467243	CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:8941025	CYP2D6	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	yes	< 0.05	74		Unknown	Toxicity	false	compared to random group of patients with depression. In the group of patients that experienced side effects the frequency (44%) of CYP2D6 *3, *4, *5, *6 carriage was higher than in a random group of patients with depression. This was more than twice the rate for the occurrence of mutant alleles in the other 56 psychiatric patients (21%) and in 80 random subjects from the general population (20%; p < 0.05).	amitriptyline; antidepressants; clomipramine; desipramine; fluoxetine; imipramine; nortriptyline; paroxetine; venlafaxine
1183689534	rs1109866	PMID:24192121	ABCB6	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.386	276		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183689529	rs4148739	PMID:24192121	ABCB1	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.	no	= 0.162	276		East Asian	Efficacy	false	Allele C was more frequent in the responders group. This association did not remain statistically significant after correction for false-discovery rate and genotypes were not significantly associated. Please note; alleles have been complemented to the plus chromosomal strand. This SNP was in strong LD with rs28401781.	citalopram; fluoxetine; paroxetine; sertraline
1183623738	CYP2C19*1; CYP2C19*2	PMID:16236141	CYP2C19	CYP2C19 *1/*1 is not associated with differences in dose-normalized plasma levels of individual enantiomers and of the active moiety when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*2 + *2/*2.	no	= 0.05	78		European	Metabolism/PK	false		fluoxetine
827923681	rs242941	PMID:17258395	CRHR1	Genotype CC is associated with increased response when treated with fluoxetine in people with major depression and high anxiety as compared to allele A.	yes	= 0.026	85		East Asian	Efficacy	false	CC was associated with a significant decrease in HAMD of 60.5 ± 9.2%, A-allele carriers had a rate of decrease of 47.2 ± 8.6% (P = 0.026)	fluoxetine
1183920937	CYP2D6*3; CYP2D6*4	PMID:22775532	CYP2D6	CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	no	> 0.05	39		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).32 patients were CYP2D6 EMs, 2 were UMs, 4 were IMs, and 1 patient was a PM. Exploratory association analysis of response to all 108 drug trials found a significant effect of CYP2D6 metabolizer status on response (Fisher's exact test: p=0.021) when comparing the patients with reduced CYP2D6 activity (IMs and PMs) to EMs or UMs, but no information regarding the direction of the association is given. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	citalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1183689783	CYP2D6*1; CYP2D6*3; CYP2D6*4	PMCID:PMC2014382	CYP2D6	CYP2D6 *3/*3 + *3/*4 + *4/*4 is associated with increased plasma concentrations of fluoxetine and decreased nor-fluoxetine concentrations when treated with fluoxetine in women with Depression as compared to CYP2D6 *1/*1.	not stated		9		European	Metabolism/PK	false	Study genotyped for *3 and *4 and grouped two non-functional alleles as PM. Study did not report exact genotype of patients.	fluoxetine
1450367689	rs559628884	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for N277K is 63.06% compared to *1 (no variants).	fluoxetine
1183944237	SLC6A4 HTTLPR short form (S allele)	PMID:10683861	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or paroxetine in people with Depressive Disorder, Major.	yes	= 0.0150	120		East Asian	Efficacy	false	PCR: (5'-GGCGTTGCCGCTCTGAATGC), and (5'-GAGGGACTGAGCTGGACAACCAC), corresponding to bases -1416-1397 and -910-889 respectively.  5-HTTLPR gave five alleles differing by 44 bp (14, 16, 18, 20, 22 copies of a repetitive sequence comprising a GC-rich 20-23 bp. The most prevalent allele of the 5-HTTLPR polymorphism for the promoter region in the Korean population was the shortest allele, the 14-copy allele. This allele is designated s and all others are designated l.	fluoxetine; paroxetine
1450367694	rs3758581	PMID:28494448	CYP2C19	Allele G is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for I331V is 45.5% compared to *1 (no variants).	fluoxetine
1183633970	rs2452600	PMCID:PMC3762623	PDLIM5	Allele T is not associated with differences in response when treated with fluoxetine in people with Depressive Disorder, Major as compared to allele C.	no	= 0.0145	185		East Asian	Efficacy	false		fluoxetine
1184169557	CYP2D6 normal metabolizers	PMID:23545896	CYP2D6	CYP2D6 normal metabolizers are associated with decreased number of failed medication trails when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder.	yes	= 0.007	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	Study observed that UM and PM both had undergone more medication trials than those with EM status (UM: median 3.5 trials (range 1-8), PM: median 5; EM: median 2 (range 1-9), IM: median 2 (range 1-7)). Significantly more non-EM than EM had undergone four or more drug trials (non-EM: 13/27 (48%) patients withgreater than or equal to4 trials; EM: 34/157 (22%) patients with greater than or equal to4 trials; P=0.007). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
655386834	rs2227631	PMID:18794724	SERPINE1	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.014	140		East Asian	Efficacy	false	(as haplotype with rs1799889-G)	citalopram; fluoxetine
1183689550	rs6946119	PMID:24192121		Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.501	215		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183846995	CYP2D6 poor metabolizer	PMID:10755579	CYP2D6	CYP2D6 poor metabolizer is associated with fetal intoxication when treated with fluoxetine.	no		1		Unknown	Other	true	Case study. Patient was on muliple medications including promethazine, methylphenidate, fluoxetine, and clonidine. The exact diplotype or genetic variation was not given.	fluoxetine
1184472154	CYP2D6*1; CYP2D6*1xN	PMID:24663076	CYP2D6	CYP2D6 *1/*1 (assigned as normal metabolizers phenotype) are associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	yes	< 0.001	56		European	Metabolism/PK	true		fluoxetine
1450367668	rs749678783	PMID:28494448	CYP2C19	Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for M255T is 29.96% compared to *1 (no variants).	fluoxetine
1183689546	rs3755047	PMID:24192121	ABCB6	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.267	282		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183689542	rs3731885	PMID:24192121	ABCB6	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.345	281		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1450367673	rs181297724	PMID:28494448	CYP2C19	Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for A161P is 23.94% compared to *1 (no variants).	fluoxetine
1450367679	rs138142612	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R329H is 37.84% compared to *1 (no variants).	fluoxetine
769171479	rs57098334	PMID:10683861	SLC6A4	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.	yes	< 1.0E-4	120	252	East Asian	Efficacy	false		fluoxetine; paroxetine
981501007	rs6265	PMID:20016225	BDNF	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.	no				East Asian	Efficacy	false	Information is minimal because full-text was not accessible.	fluoxetine
1183689538	rs1109867	PMID:24192121	ABCB6	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.384	283		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1450367650	rs72552267	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R132Q is 37.45% compared to *1 (no variants).	fluoxetine
1183846978	CYP2D6 poor metabolizer	PMID:10208643	CYP2D6	CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.	yes	< 0.05	12		Unknown	Metabolism/PK	false	Subjects were phenotyped using sparteine. CYP2D6 PMs had more than twofold greater AUC of R-fluoxetine than EMs, and more than a 12-fold greater AUC of S-fluoxetine than EMs (statistically significant). The half-life of R-fluoxetine and S-fluoxetine was 2.6 and 1.1 days respectively in EMs and 9.5 and 6.1 days in PMs (statistically significant).  The elimination half-life and AUC of R-norfluoxetine was not significantly different between EMs versus PMs. S-norfluoxetine half-life in EMs was 5.5 days and in PMs 17.4 days (p=0.007).	fluoxetine
1183678553	CYP2D6*1; CYP2D6*17	PMID:17470523	CYP2D6	CYP2D6 *17 is associated with decreased clearance of fluoxetine as compared to CYP2D6 *1.	not stated					Metabolism/PK	false	Intrinsic clearance was 8.17% that of CYP2D6*1. In vitro study in microsomes from transfected insect cells.	fluoxetine
1183689563	rs182694	PMID:24192121	ABCG1	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.642	278		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1448285579	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:27439447	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	yes	= 0.0066	102		Central/South Asian	Efficacy	false		fluoxetine
1183846985	CYP2D6 poor metabolizer	PMID:8941024	CYP2D6	CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.	yes	< 0.05	20		Unknown	Metabolism/PK	false	Subjects phenotyped with debrisoquin. AUC and elimination half-life were determined. AUC was 481 + 245 for EMs and 1871 + 328 for PMs (p <0.05). The terminal elimination half-life for EMs was 24 + 7 hours and for PMs 76 + 14 hours (p <0.05).	fluoxetine
1450367659	rs150152656	PMID:28494448	CYP2C19	Allele T is not associated with clearance of fluoxetine in insect microsomes as compared to allele C.	no					Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for T130M is 94.04% compared to *1 (no variants).	fluoxetine
1184168783	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:20584552	SLC6A4	SLC6A4 HTTLPR short form (S allele) is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	no		64		Multiple groups, probably White (Spanish mental health center).	Dosage,Efficacy	false	"There was no placebo group in this trial.  The association tested was with response at 4 weeks.  The alleles were referred to as ""short"" and ""long"" rather than by genotype.  The Long group was further subdivided into ""La"" and ""Lg"" (reported for rs25531)."	fluoxetine
1183678545	CYP2D6*1; CYP2D6*10	PMID:17470523	CYP2D6	CYP2D6 *10 is associated with decreased clearance of fluoxetine as compared to CYP2D6 *1.	not stated					Metabolism/PK	false	Intrinsic clearance was 7.54% that of CYP2D6*1. In vitro study in microsomes from transfected insect cells.	fluoxetine
1183846990	CYP2D6 poor metabolizer	PMID:12404686	CYP2D6	CYP2D6 poor metabolizers are not associated with increased risk of hyponatraemia when treated with fluoxetine or paroxetine in people with Depression as compared to CYP2D6 normal metabolizers.	not stated		20		European	Toxicity	false	CYP2D6 genotype analysis was performed for the *1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13,*14, *15 and *16 alleles. EM are defined as having at least one functional allele. PMs are not clear classified.	fluoxetine; paroxetine
1183689554	rs3747802	PMID:24192121	ABCB1	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.542	277		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183623532	CYP2D6*1; CYP2D6*1xN; CYP2D6*2; CYP2D6*2xN	PMID:22733128	CYP2D6	CYP2D6 *1/*1xN + *2/*2xN are associated with increased likelihood of discontinuation when treated with amitriptyline or fluoxetine in people with Depressive Disorder, Major.	yes	< 0.01	100		Unknown	Toxicity	false	Patients received either 20 mg/day fluoxetine or 75 mg/day amitriptyline. 4 UMs (more than two functional CYP2D6 alleles) discontinued treatment within the first 4 weeks, whereas no PM (no functional CYP2D6 allele) did so within 12 weeks. There were differences across CYP2D6 groups in the rate of ADP discontinuation at week 4 (P<0.01). The CYP2D6 activity value assigned to the reference allele *1 and *2 was 1, to *3, *4, *4xN, *5 and *6 was 0, to *10 or *17 was 0.5 and to multiplications of active alleles (*1xN or *2xN) was 2. Alleles or diplotypes found in study population or if patients received any co-medication were not reported.	amitriptyline; fluoxetine
1450367635	rs200346442	PMID:28494448	CYP2C19	Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R124Q is 9.75% compared to *1 (no variants).	fluoxetine
1184509821	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:14573314	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of Sleep Initiation and Maintenance Disorders when treated with fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	yes	= 0.02	36		European	Toxicity	false		fluoxetine
981500777	rs4713916	PMID:20709156	FKBP5	Allele A is associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele G.	yes	= 0.01	1944	908	Multiple groups	Efficacy	false	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	citalopram; fluoxetine; mirtazapine; paroxetine; Selective serotonin reuptake inhibitors; venlafaxine
1184511344	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:16302021	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	< 0.001	224		East Asian	Efficacy	false	Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment.	fluoxetine
1450367645	rs200150287	PMID:28494448	CYP2C19	Allele G is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R125G is 17.31% compared to *1 (no variants).	fluoxetine
655386848	rs1799889	PMID:18794724	SERPINE1	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.014	140		East Asian	Efficacy	false	(as part of haplotype with rs2227631-G)	citalopram; fluoxetine
1448285601	SLC6A4 HTTLPR short form (S allele); SLC6A4 L allele-rs25531C; SLC6A4 L allele-rs25531T	PMID:27439447	SLC6A4	SLC6A4 L allele-rs25531T/L allele-rs25531T is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531T + L allele-rs25531C/L allele-rs25531T.	no	= 0.0818	102		Central/South Asian	Efficacy	false	Symptom improvement based on the HAM-D17 scale.	fluoxetine
981500787	rs1360780	PMID:20709156	FKBP5	Allele T is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele C.	no	= 0.36	2302	1210	European	Efficacy	false	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	citalopram; fluoxetine; mirtazapine; paroxetine; Selective serotonin reuptake inhibitors; venlafaxine
1450664580	rs3758581	PMID:21692664	CYP2C19	Allele G is not associated with sensitivity to celecoxib, fluconazole, fluoxetine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine or troglitazone as compared to allele A.	no					Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	celecoxib; fluconazole; fluoxetine; ketoconazole; omeprazole; sertraline; ticlopidine; tranylcypromine; troglitazone
1450367621	rs147255955	PMID:28494448	CYP2C19	Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for L16F is 74.14% compared to *1 (no variants).	fluoxetine
1450367626	rs118203756	PMID:28494448	CYP2C19	Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for G91R is 77.77% compared to *1 (no variants).	fluoxetine
1183624055	CYP2D6*1; CYP2D6*4; CYP2D6*6	PMID:14726986	CYP2D6	CYP2D6 *4 + *6 is not associated with increased differences in C/D plasma concentrations of norfluoxetine or active moiety when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	no	= 0.01	64		European	Metabolism/PK	false	Diplotypes found in study: *1/*1 (41); *1/*4 (17); *1/*6 (2); *4/*4 (1); *1/*1XN (3).	fluoxetine
1184472165	CYP2D6*1; CYP2D6*1xN; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:24663076	CYP2D6	CYP2D6 *5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6 are associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	yes	< 0.001	30		European	Metabolism/PK	true		fluoxetine
1451503480	CYP2D6*1; CYP2D6*4; CYP2D6*10	PMCID:PMC8441053	CYP2D6	CYP2D6 *1/*1 + *10/*10 + *1/*4 + *1/*10 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP2D6 *10/*4 (assigned as intermediate metabolizer phenotype) .	yes	= 0.01	60		Latino	Metabolism/PK	false	"For CYP2D6 phenotypes were assigned as CYP2D6 extensive (*1/*1, *10/*10, *1/*4, *1/*10), intermediate (*10/*4) and poor
(*4/*4) metabolizers using CYP2D6*4 (rs3892097), and CYP2D6*10 (rs1065852). Also, CYP2D6 extensive metabolizers had almost twice
the value of norfluoxetine/fluoxetine ratios (0.9 (0.7–1.7)) than
patients with CYP2D6 intermediate metabolism (0.5 (0.3–0.8))"	fluoxetine
981500798	rs3800373	PMID:20709156	FKBP5	Allele C is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele A.	no	= 0.09	2082	1108	European	Efficacy	false	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	citalopram; fluoxetine; mirtazapine; paroxetine; Selective serotonin reuptake inhibitors; venlafaxine
1184518500	CYP2C19*1; CYP2C19*14	PMID:21692664	CYP2C19	CYP2C19 *14 is associated with decreased sensitivity to fluoxetine and sertraline as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine."	fluoxetine; sertraline